Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.31M P/E - EPS this Y 42.70% Ern Qtrly Grth -
Income -14.42M Forward P/E -0.85 EPS next Y 22.40% 50D Avg Chg -36.00%
Sales 145.8k PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 0.79 EPS next 5Y - 52W High Chg -60.00%
Recommedations 2.00 Quick Ratio 10.42 Shares Outstanding 6.77M 52W Low Chg 22.00%
Insider Own 18.80% ROA -65.50% Shares Float 5.50M Beta 61.68
Inst Own 13.80% ROE -105.30% Shares Shorted/Prior 40.50K/6.68K Price 2.84
Gross Margin 100.00% Profit Margin - Avg. Volume 75,067 Target Price 10.50
Oper. Margin -16,687.47% Earnings Date May 12 Volume 14,187 Change 0.71%
About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

BioRestorative Therapies, Inc. News
04/16/24 BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
04/14/24 10 Micro-Cap Healthcare Stocks Insiders Are Buying
04/08/24 BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
04/03/24 BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
04/03/24 BioRestorative Therapies Full Year 2023 Earnings: Beats Expectations
04/01/24 BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
03/11/24 BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
02/15/24 Favourable Signals For BioRestorative Therapies: Numerous Insiders Acquired Stock
02/14/24 BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
02/06/24 BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
02/05/24 BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
02/01/24 BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
12/12/23 BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
12/03/23 11 Most Volatile Stocks Under $5 For Day Trading
10/09/23 BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City
10/02/23 QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
09/18/23 Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”
09/12/23 EXCLUSIVE: Stem Cell Focused BioRestorative Ventures Into $63B Aesthetics Market Via Supply Agreement With Evolutionary Biologics
09/12/23 BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics
09/08/23 BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
BRTX Chatroom

User Image gobuckeyes21 Posted - 17 minutes ago

$BRTX new all time lows !!! I called it and this will be below a dollar soon. Watch. Lance will screw you. That’s what he does.

User Image Omega_Proxy Posted - 2 hours ago

$BRTX Hope y'all brought Vaseline. Fools keep trying to catch a pump. We're the ones getting pumped.

User Image PaddlingUpShitCreek Posted - 3 hours ago

$BRTX | Jesus!

User Image gobuckeyes21 Posted - 7 hours ago

$BRTX still holds true! Runnnnnnnn!

User Image Stroked514 Posted - 6 days ago

$TWG in here while holding $SPEC $BRTX $WISA $HKD

User Image Iwanttomakemoney3 Posted - 6 days ago

$BRTX little volume comes we will see a quick $1.60 pop

User Image Iwanttomakemoney3 Posted - 6 days ago

$BRTX double bottom play

User Image Gorilla_Trading Posted - 6 days ago

$BRTX Onwards & upwards 🎯

User Image Crypto_Vampire Posted - 6 days ago

$BRTX

User Image Gorilla_Trading Posted - 6 days ago

$BRTX large potential Double bottom forming.

User Image Belle0314 Posted - 1 week ago

$BRTX Simply Wall Street.

User Image Stocksrunner Posted - 1 week ago

Wednesday's Remarkable Rebounds: Stocks Surging from Open to Close 💹 🚀 $BRTX Bounces Back BRTX began the session at $1.24 and jumped to $1.40 by the close, achieving a 12.90% rise. #BRTX #TradingDay

User Image frogoracletrading Posted - 1 week ago

$BRTX Support / Resistance Levels Curling off 1.20 support. Watch for another test of the GAP. Larger Image: https://s3.tradingview.com/snapshots/y/yA3YFgHO.png

User Image VrtcIl Posted - 1 week ago

Do not chase $BRTX now, as doing so would require setting a stop-loss at a considerable distance from the entry point. Waiting for more favorable conditions can lead to a more manageable risk-reward ratio. Price: 1.44 Float: 3.7M Short Float: 0.8 % 💰 Dollar Volume: 11.9K ℹ️ USA | Biotechnology

User Image Del_Aux Posted - 1 week ago

$BRTX where are u?

User Image Obiaard Posted - 1 week ago

$BRTX Curious where u found this

User Image Del_Aux Posted - 1 week ago

$BRTX let's boost----

User Image TheGenieOfWallstreet Posted - 1 week ago

40 new discord members overnight. I’m alerting nothing but heat today, it’s time to make some money.😈 $SOFI $PALI $WISA $AMD $BRTX

User Image Belle0314 Posted - 1 week ago

$BRTX

User Image Mintymom Posted - 1 week ago

$BRTX

User Image Stroked514 Posted - 1 week ago

$BRTX $10

User Image MoonMarket_ Posted - 1 week ago

$BRTX $PALI $INVO $WISA

User Image gobuckeyes21 Posted - 1 week ago

$BRTX badda bing!

User Image gobuckeyes21 Posted - 1 week ago

$BRTX told ya. Lance always screws the shareholders! More bag holders per usual. If you can get out at even money, do it.

User Image Stroked514 Posted - 1 week ago

$BRTX I’ll swing this for the fences tomorrow maybe.

User Image MaVwapMacd Posted - 1 week ago

$BRTX

User Image Stroked514 Posted - 1 week ago

$WISA $BRTX primed?

User Image stockregion Posted - 1 week ago

Breakthrough in Back Pain Treatment: BioRestorative Therapies' Major FDA Milestone. In an era where chronic back pain has emerged as a prevalent affliction affecting millions worldwide, a glimmer of hope shines through the efforts of BioRestorative Therapies, Inc. (BRTX). The company recently announced a significant leap forward in its quest to offer a revolutionary treatment for lower back pain caused by degenerative disc disease. The U.S. Food and Drug Administration (FDA) has granted clearance for an amendment to the Phase 2 clinical study protocol of BRTX-100, a highly anticipated autologous stem cell therapy product. The amendment to the clinical study protocol marks a pivotal moment in the development of BRTX-100, enabling a more streamlined path towards evaluating its efficacy and safety in patients suffering from chronic lumbar disc disease. $BRTX https://stockregion.app/p/therapy-company-secures-fda-clearance

User Image StockG86 Posted - 1 week ago

$BRTX power hour and AH surge .. 🚀🚀

User Image Stroked514 Posted - 1 week ago

$BRTX need a breakout of the wedge! Let’s go. Shares are getting locked up. Make the shorts pay a premium.

Analyst Ratings
Roth MKM Buy Aug 14, 23
Roth Capital Buy Dec 7, 22
Maxim Group Buy Sep 28, 22
Roth Capital Buy Dec 1, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Broadrick Dale 10% Owner 10% Owner Nov 27 Sell 1.89 278 525 327,295 12/01/23
Broadrick Dale 10% Owner 10% Owner Sep 14 Buy 1.6 20,000 32,000 327,573 09/18/23
Broadrick Dale 10% Owner 10% Owner Jul 27 Buy 2.8 1,000 2,800 306,073 07/28/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jul 25 Buy 2.44 4,200 10,248 184,418 07/25/23
Silva Francisco VP of Research and D.. VP of Research and Development Mar 31 Buy 3.56 747 2,659 159,690 04/04/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 27 Buy 3.01 200 602 186,921 01/30/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 18 Buy 3.1 400 1,240 186,521 01/20/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 09 Buy 3.08 100 308 186,121 01/10/23
ALSTODT LANCE President, CEO, COB President, CEO, COB Dec 23 Buy 3.01 300 903 186,021 12/28/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Dec 07 Buy 2.9861 1,800 5,375 185,721 12/07/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Nov 18 Buy 2.8765 1,000 2,876 183,921 11/21/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Sep 22 Buy 2.92 200 584 182,921 09/23/22
Silva Francisco VP of Research and D.. VP of Research and Development Aug 26 Buy 3.29 5,723 18,829 12,136 09/09/22
Silva Francisco VP of Research and D.. VP of Research and Development Aug 26 Sell 3.39 3,958 13,418 158,156 09/09/22
Broadrick Dale 10% Owner 10% Owner Jul 06 Buy 3.12 1,200 3,744 298,573 07/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jul 12 Buy 2.95 700 2,065 182,721 07/13/22
Broadrick Dale 10% Owner 10% Owner Jun 30 Buy 3.0789 1,900 5,850 297,373 07/05/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 30 Buy 3.0981 1,100 3,408 182,021 07/01/22
Broadrick Dale 10% Owner 10% Owner Jun 15 Buy 3.76 3,200 12,032 294,773 06/17/22
Kristal Robert Eugene Chief Financial Offi.. Chief Financial Officer Jun 15 Buy 3.61 194 700 7,994 06/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 15 Buy 3.6822 700 2,578 180,321 06/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 14 Buy 3.9119 500 1,956 179,621 06/15/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 13 Buy 3.95 200 790 179,121 06/14/22
Broadrick Dale 10% Owner 10% Owner Jun 09 Buy 4.25 1,600 6,800 290,273 06/13/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 08 Buy 4.28 100 428 178,921 06/09/22
Broadrick Dale 10% Owner 10% Owner Jun 03 Buy 4.92 4,200 20,664 282,673 06/07/22
Kristal Robert Eugene Chief Financial Offi.. Chief Financial Officer Jun 07 Buy 4.56 200 912 7,800 06/07/22
Broadrick Dale 10% Owner 10% Owner Jun 02 Buy 4.6878 1,000 4,688 278,473 06/06/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jun 01 Buy 4.6 200 920 178,821 06/03/22
Broadrick Dale 10% Owner 10% Owner May 26 Buy 3.51 4,950 17,374 259,303 05/31/22
Broadrick Dale 10% Owner 10% Owner May 26 Sell 3.44 2,000 6,880 257,303 05/31/22
ALSTODT LANCE President, CEO, COB President, CEO, COB May 02 Buy 3.95 400 1,580 175,921 05/02/22
Kristal Robert Eugene Chief Financial Offi.. Chief Financial Officer Apr 08 Buy 5.71 7,600 43,396 7,600 04/11/22
Broadrick Dale 10% Owner 10% Owner Apr 06 Buy 5.66 2,500 14,150 254,353 04/08/22
Broadrick Dale 10% Owner 10% Owner Mar 29 Buy 4.89 15,700 76,773 316,972 04/01/22
Broadrick Dale 10% Owner 10% Owner Mar 01 Buy 4.87 155,950 759,476 205,853 03/29/22
ALSTODT LANCE President, CEO, COB President, CEO, COB Jan 24 Buy 3.4 1,470 4,998 163,083 01/24/22